Temple Spinout ExpressCells Adds New Investors to Meet ‘Rapidly Growing Demand’
ExpressCells, a gene editing technology company spun out of Temple University, has raised $590,500 in an equity financing.
Founded in 2018, ExpressCells is using its own proprietary genome editing technology in combination with CRISPR to create advanced “knock-in” cell lines to enhance drug discovery and support other types of biological research. The speed of the process, according to the company, allows it to insert up to three genes into the same cell line months faster than other technologies.
CRISPR, an acronym for clustered regularly interspaced short palindromic repeats, is a technique for inserting new genetic information into living cells to alter DNA sequences and modify gene function.
ExpressCells’ series A2 round, which was oversubscribed by 18%, was an extension of its $800,000 Series A round completed in 2019.
The financing included new and existing investors.
Read the full article here.